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INTRODUCTION
Globally, cancer is diagnosed in approx-
imately 13 million people each year.
Approximately 1.6 million cancer patients
are seen by cancer clinics across the United
States (US) at this time. Over the next two
decades, cancer incidence is estimated to
increase by approximately 45% to 2.3 mil-
lion (1). In the US, the 5-year relative sur-
vival rate of patients diagnosed with cancer
in 1975–1977 was 50%, improving to 68%
in the period 1999–2005. Novel targeted
chemotherapeutic agents and improved
diagnostic techniques are responsible for
this increased survival. However, with the
improvement in life expectancy, the adverse
effects of chemotherapeutic agents, espe-
cially cardiotoxicity, is an emerging health
problem. Cardiovascular toxicity on its
own has a detrimental effect on both the
quantity and quality of life independent of
the oncological prognosis.
Currently, more than two million
women with breast cancer are at risk of
anthracycline cardiotoxicity in the US (2).
Human epidermal growth factor recep-
tor II (HER2) positive disease comprises
approximately 25% of all breast cancer
patients and is associated with more aggres-
sive disease activity and worse progno-
sis. Trastuzumab, a humanized mono-
clonal antibody used for patients with
HER2 positive breast cancer in conju-
gation with chemotherapy, can provide
longer survival and 20% reduction in
risk of death (3). Cardiotoxicity becomes
an important health issue because up to
27% of women with breast cancer receiv-
ing anthracyclines, cyclophosphamide, and
trastuzumab showed cardiac dysfunction
(3). Breast cancer mortality is reduced
by approximately one-third, but the risk
of heart toxicity is five times more likely
for women receiving trastuzumab than
women receiving standard therapy alone
(4). Patients showing signs of cardiotox-
icity often require a dose reduction, a
change in the schedule dosing or even ces-
sation of treatment with attendant conse-
quences. Many patients with an asympto-
matic decrease in left ventricular ejection
fraction (LVEF) are receiving neither the
American College of Cardiology/American
Heart Association Class I-indicated treat-
ments nor cardiovascular specialty consul-
tation (5).
Concern for cardiotoxicity is not
restricted to breast cancer survivors. Based
on National Cancer Institute (NCI) data,
the number of new renal cancer patients
in 2013 is expected to be 65,000. In
Europe, the incidence of renal cell car-
cinoma (RCC) has doubled in the last
three decades (6). Improved treatment
strategies have increased the 5-year sur-
vival of patients with RCC from 50% in
1975–1977 to 72% in 2002–2008. Within
the last decade, the US Food and Drug
Administration (FDA) has approved six
drugs for the treatment of RCC includ-
ing multitargeted tyrosine kinase inhibitors
(TKIs); antibodies to vascular endothelial
growth factor (VEGF); and mammalian
target of rapamycin (mTOR) inhibitors.
Sunitinib, a novel multitargeted TKI, has
proven efficacy in advanced metastatic
RCC demonstrating an increased median
progression free survival of 8.3 months
in these patients (7). In a study by Hall
et al. (8), five of the approved targeted
therapy drugs (sorafenib, pazopanib, beva-
cizumab, everolimus, and temsirolimus)
have cardiotoxic side effects. In this 159-
patient study, 73% of patients experienced
some form of cardiotoxicity ranging from
hypertension to severe heart failure (8). In
a cohort of patients with renal and non-
renal carcinoma, sunitinib was found to
be associated with a 3.3-fold higher risk of
heart failure (9). Other targeted agents such
as imatinib mesylate, Dasatinib, Nilotinib,
and Sorafenib are prescribed for treatment
of various hematological malignancies,
hepatocellular carcinoma (HCC), gastroin-
testinal stromal tumor (GIST), and myelo-
proliferative/myelodysplastic diseases and
have been shown to be strongly associ-
ated to cardiotoxicity (10–13). Imatinib has
been shown to be associated with decline
in LVEF, especially in patients with other
comorbidities including coronary artery
disease, diabetes, and hypertension (10).
CURRENT PRACTICE FOR DETECTING
CHEMOTHERAPY-INDUCED
CARDIOTOXICITY
The overlap of symptoms between diag-
nosis of cancer, symptoms of cardiac dys-
function, and the wide spectrum of car-
diac injury caused by chemotherapy makes
the diagnosis of cardiotoxicity a challenge.
These side effects can be categorized as:
(a) direct cytotoxic effects of chemotherapy
resulting in systolic dysfunction; (b) car-
diac ischemia; (c) cardiac arrhythmia; (d)
pericarditis; (e) or chemotherapy-induced
repolarization abnormalities. Early diag-
nosis of these abnormalities requires rou-
tine baseline and post-chemotherapy mon-
itoring of patients’ cardiac status using
symptoms, vital signs, and simple ancil-
lary tests such as an electrocardiogram
(ECG), echocardiogram, serum troponin
levels, serum brain natriuretic peptide
(BNP) where applicable and, less fre-
quently, radionuclide angiocardiography.
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The most common practice in the eval-
uation of cardiac function for patients on
chemotherapy is ejection fraction assess-
ment by echocardiography. Cardiotoxicity
is most commonly defined as a reduction
of the LVEF of>5% to that of a<55% with
symptoms of heart failure or an asymp-
tomatic reduction of the LVEF of >10 to
<55% (14). Serial evaluation of LVEF mul-
tiple gated acquisition scan (MUGA) is
currently used widely to monitor for car-
diotoxicity secondary to chemotherapeutic
drugs. In comparison to two-dimensional
echocardiography, MUGA has lower inter-
and intra-observer variability in measure-
ment of LVEF. However, it carries risk
of radiation exposure and, like the two-
dimensional (2D) echocardiogram, pro-
vides limited information regarding car-
diac structure and diastolic function, which
limits its ability to detect subclinical
myocardial damage (15, 16).
Three-dimensional (3D) echocardiog-
raphy is reported to be more accurate
than 2D echocardiogram in terms of intra-
and inter-observer as well as test–retest
variability (17) and cardiac magnetic res-
onance imaging for estimation of car-
diac volumes and EF measurement (18).
The myocardial motion during a systole is
a complex phenomenon with shortening
both longitudinally and circumferentially
while thickening radially. Early cardiotoxic
change in one of the myocardial motion
can be compensated by another, giving
a normal EF on testing. Chemotherapy-
induced cardiotoxicity is regional, caus-
ing an ultrastructural damage that can
precede the functional change of reduc-
tion in LVEF. Hence, assessing myocar-
dial mechanics through deformation using
strain analysis has emerged as a novel
method to detect these early changes in
myocardial function. Color tissue Doppler
imaging uses the frequency shift between
the original and tissue-reflected sono-
graphic waves to calculate various cardiac
functional parameters such as velocity, dis-
placement, strain, and strain rate (SR). As
the Doppler can only measure and detect
changes in the direction of the sonographic
beam, the Doppler-derived strain measure-
ments have several restrictions such as
angle dependency and inter-observer vari-
ability. Vector velocity imaging is another
echocardiographic technique to quantita-
tively analyze myocardial mechanics, which
is relatively angle independent. This tech-
nique is based on detecting frame-to-frame
analysis of unique natural acoustic myocar-
dial features referred to as“speckles.”These
“speckles” from the myocardium in con-
junction with 2D or 3D echocardiogra-
phy are analyzed for motion in longitudi-
nal, radial, and circumferential directions
simultaneously. This is a semi-automated
technique where manual delineation of
the myocardium, followed by automated
tracking software using a complex algo-
rithm for the measurement of instanta-
neous velocity vector for individual speck-
les measured by analyzing their frame-
to-frame spatial variability. These speck-
les are then added to give global val-
ues for myocardial functional parameters.
The ideal tracking requires good image
quality, optimum frame rate and man-
ual readjustment of tracking if neces-
sary for proper wall motion analysis by
the software (Figure 1). The 3D analy-
sis of the speckle tracking has the the-
oretic advantage of tracking the speckle
in all of the three dimensions simulta-
neously, which is not possible with 2D
speckle tracking and Doppler tracking, and
therefore, permits comprehensive analysis
of cardiac function. Unlike LVEF mea-
surement, speckle tracking allows complex
analysis of all the physiological myocar-
dial activity during a cardiac cycle includ-
ing movement in longitudinal, circum-
ferential, and radial direction and mea-
surement of the twist and torsion of the
heart. In a few studies, the peak systolic
radial, longitudinal, and circumferential
strain decreases with elevation in plasma
troponin have been validated to be early
predictors of cardiotoxicity by anthracy-
clines and trastuzumab (19). In general,
a reduction of longitudinal strain >10%
from baseline after 3 months may predict
future cardiac injury with a sensitivity and
FIGURE 1 | Pre- and post-chemo strain imaging showing two chamber, three chamber, four chamber, and bull’s eye view. The white and blue areas in
ventricular strain imaging represent area of abnormal strain imaging. Global average longitudinal strain reduced from −21.9 to −13.4% after chemotherapy.
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specificity of about 78 and 79%, respec-
tively (19).
FUTURE PROSPECTS FOR PREVENTION
OF CHEMOTHERAPY-INDUCED
CARDIOTOXICITY
There is evidence of the use of angiotensin
converting enzyme inhibitors (ACE-I)
both for treatment and prophylaxis
in chemotherapy-induced cardiotoxicity.
Early treatment with these drugs seems
to prevent and, to some extent, reverse
the cardiotoxic effects of chemotherapeu-
tic drugs (20). The US FDA has approved
dexrazoxane, a derivative of ethylene-
diamine tetraacetic acid (EDTA), for use
in adults if cumulative doses of dox-
orubicin exceed 300 mg/m2 (4). It acts
by preventing free radical formation at
the cellular level but can also decrease
the efficacy of some of chemotherapeu-
tic agents by changing their pharmaco-
kinetics. Other strategies are still under
development and traditional approaches to
reduce chemotherapy-induced cardiotoxi-
city including establishing stringent LVEF
criteria for patient selection, monitoring
cardiac function during therapy, and dis-
continuing potentially cardiotoxic ther-
apy when cardiotoxicity arises still are
the only ones available for clinicians
currently.
INTEGRATION OF SPECIALTIES
Cardio-oncology and onco-cardiology are
terms used to describe an integrated
approach between cardiologists and oncol-
ogists. While chemotherapy is beneficial in
destroying malignant cells, it can simulta-
neously cause injury or death to myocardial
cells, which is described as cardiotoxicity.
In the setting of neoadjuvant and adju-
vant treatment and a laudable goal, a can-
cer survivor of today does not become the
heart failure patient of tomorrow should be
pursued.
Congestive heart failure contributes
to the mortality and morbidity of can-
cer patients if not recognized early. In
general, chemotherapeutic cardiac toxic-
ity is classified as type 1 chemotherapy-
related LV systolic dysfunction caused
by agents such as doxorubicin, epiru-
bicin, idarubicin, cyclophosphamide, and
docetaxel. Type 2-mediated cardiotoxicity
resulting from trastuzumab is generally
not dose related and may be associated
with reversible myocardial dysfunction.
This class of agents also includes lapatinib,
sunitinib, imatinib, and bevacizumab. This
cardiac injury may occur early during
the cancer treatment or may be delayed
months to years after cancer has been
successfully treated. Accurate cardiovascu-
lar monitoring at regular intervals dur-
ing chemotherapy is particularly impor-
tant with prolonged adjuvant therapy. With
the use of vector velocity imaging or
strain echocardiography, early detection
of chemotherapy-induced cardiac injury
is now within the realm of clinical prac-
tice. The aim of cardio-oncology collab-
oration is not to discontinue or reduce
the dose of chemotherapy, which would
reduce the efficacy of treatment, but to
identify cardiotoxicity early and intervene
so that congestive heart failure does not
supervene.
The inter-disciplinary and integrative
management of cancer patients with car-
diovascular risks or patients who develop
cardiovascular injury is: (a) early detec-
tion of patients at risk for cardiotoxic-
ity; (b) early institution of cardioprotec-
tive agents; (c) preventing the mitigation of
the chemotherapeutic agent as far as possi-
ble; (d) eliminating as much of the cancer
as possible with the appropriate doses of
chemotherapeutic agent while minimizing
collateral damage, i.e., cardiotoxicity.
CONCLUSION
Virtually all anti-cancer drugs target tumor
cell death that may result in collateral
injury to healthy tissues. Bone marrow
suppression and gastrointestinal toxici-
ties associated with chemotherapy are
well recognized. Much less recognized,
however, are the cardiotoxic effects of
the cancer treatment. These side effects
can cause systolic dysfunction, cardiac
ischemia, cardiac arrhythmia, pericardi-
tis, or chemotherapy-induced repolariza-
tion abnormalities. Common factors that
increase a patient’s risk of developing car-
diotoxic effects include cumulative dose,
route of administration, age, prior irradia-
tion, concomitant administration of other
chemotherapeutics, and underlying heart
disease. Radiation therapy (not discussed
in this monograph) may result in coro-
nary artery disease, valvular heart disease,
pericardial injury, and myocardial disease
from eventual fibrotic changes that occur
post-radiation. Cardiovascular disease and
cancer are the two leading causes of death
in the USA; together they are respon-
sible for nearly half of all deaths (21).
As the survival population of the cancer
patients increases, the acute and chronic
cardiovascular effects of these drugs will
become increasingly important. Therefore,
the risk of cardiac toxicity should be bal-
anced against the benefits of a particular
chemotherapeutic agent based on individ-
ual case for optimal benefit to the patient.
Much research is still needed to develop
ideal guidelines to prevent or minimize
cardiac injury in cancer patients undergo-
ing chemotherapy. Early recognition using
sensitive diagnostic techniques affords an
opportunity for early treatment of these
cardiotoxic effects. The Oncologist and
cardiologist working in collaboration for
patient care can ensure early diagnosis to
improve quality of life and survival of the
patients.
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